Document Detail

Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women.
MedLine Citation:
PMID:  7517835     Owner:  NLM     Status:  MEDLINE    
This multicentre open 6-week study evaluated the efficacy, safety and tolerability of fluvastatin, the first fully synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, in elderly women with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly women (mean age 68 +/- 5 years) with primary hypercholesterolaemia [low density lipoprotein (LDL) cholesterol > 160 mg/dl] were enrolled in the trial. Fluvastatin 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total cholesterol, LDL cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, apolipoproteins B (apo B) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total cholesterol, LDL cholesterol, triglyceride, HDL cholesterol, apo B and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, fluvastatin significantly (p < 0.001, ANOVA test) reduced total cholesterol, LDL cholesterol and apo B levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total cholesterol, -21%; LDL cholesterol, -27%). The total cholesterol: HDL cholesterol ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the patients showed a reduction > or = 20% for LDL cholesterol. Triglycerides were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)
G Baggio; O De Candia; P L Forte; F Mello; A Andriolli; S Donazzan; G Valerio; M Milani; G Crepaldi
Related Documents :
17456295 - Provision of laboratory services for lipid analysis in the united kingdom.
17039515 - Hypocholesterolemia in chronic anemias with increased erythropoietic activity.
9808595 - Associations between lipoproteins and the progression of coronary and vein-graft athero...
14613505 - Reproducibility of the serum lipid response to coffee oil in healthy volunteers.
19117545 - Endoplasmic reticulum stress plays a central role in development of leptin resistance.
11934435 - Dietary modulation of mitochondrial dna deletions and copy number after chemotherapy in...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Drugs     Volume:  47 Suppl 2     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1994  
Date Detail:
Created Date:  1994-08-09     Completed Date:  1994-08-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  59-63     Citation Subset:  IM    
Institute of Internal Medicine, University of Padua, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholesterol / blood
Fatty Acids, Monounsaturated / therapeutic use*
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hyperlipoproteinemia Type II / drug therapy*
Indoles / therapeutic use*
Lipids / blood
Reg. No./Substance:
0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 0/Lipids; 57-88-5/Cholesterol; 93957-54-1/fluvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia.
Next Document:  Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia.